1. Institut National De La Sante Et De La Recherche Medicale (23 from 1,743 patents)

2. Université´ D'aix-marseille (21 from 230 patents)

3. Institut Jean Paoli & Irène Calmettes (17 from 26 patents)

4. Centre National De La Recherche Scientifique (8 from 5,081 patents)

5. Centre Leon Berard (8 from 33 patents)

6. Universite Claude Bernard – Lyon1 (5 from 209 patents)

7. Other (4 from 832,843 patents)

8. Université De Nantes (2 from 141 patents)

9. Centre National De La Recherche Scientifique-cnrs (2 from 65 patents)

10. Inserm (institut National De La Sante Et De La Recherche Medicale) (2 from 38 patents)

11. Eli Lilly and Company (1 from 4,446 patents)

12. Cnrs (1 from 63 patents)

13. Glaxosmithkline Intellectual Property Development Limited (230 patents)

14. Université Claude Bernard Lyon I (50 patents)

15. Aix-marseille Université (11 patents)

1. 12419964 - Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload

2. 12398206 - Antibodies having specificity for nectin-4 and uses thereof

3. 12258400 - Antibodies having specificity for BTN2 and uses thereof

4. 12247075 - BTN3A binding proteins and uses thereof

5. 12049500 - Anti-nectin-4-antibodies and uses thereof

6. 11987631 - Anti-BTN3A antibodies and their use in treating cancer or infectious disorders

7. 11945871 - Anti-BTN3A antibodies and their use in treating cancer or infectious disorders

8. 11904004 - Anti-CD277 antibodies

9. 11572409 - Antibodies having specificity for BTN2 and uses thereof

10. 11180556 - Antibodies directed against ICOS and uses thereof

11. 10745482 - Antibodies directed against ICOS and uses thereof

12. 10716838 - Anti-CD277 antibodies

13. 10675357 - Antibodies having specificity to nectin-4 and uses thereof

14. 10633446 - Antibodies directed against ICOS and uses thereof

15. 10273306 - Antibodies directed against ICOS for treating graft-versus-host disease